Transarterial infusion of cisplatin and doxorubicin in bladder cancer

Acta Oncologica

Volumn 36, Issue 2, 1997, Pages 175-181

  Mokarim, Abul ^a   Uetani, Masataka ^a   Sakamoto, Ichiro ^a   Hayashi, Nobuyuki ^a   Nomata, Koichiro ^a   Ohtani, Hiroshi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030935305     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869709109227     Document Type: Article

References (28)

1. Skinner DG. Current perspectives in the management of high grade invasive bladder cancer. Cancer 1980; 45: 1866-74.
2. Whitemore WF. Integrated irradiation and cystectomy for bladder cancer. Br J Urol 1980; 52: 1-9.
3. Raghvan D. Pre-emptive (neo-adjuvant) intravenous chemotherapy for invasive bladder cancer. Br J Urol 1988; 61: 1-8.
4. Scher HI, Herr H, Sternberg C, et al. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with M - VAC regimen. Br J Urol 1989; 64: 250-6.
5. Logothetics CJ, Samuels ML, Ogden S. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol 1985; 134: 460-4.
6. Logothetics CJ, Samuels ML, Selig DE, Wallace S, Johnson DE. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin and cisplatin (CISCA) in the management of selected patients with invasive urothelial tumors. Cancer Treat Rep 1985; 69: 33-7.
7. Japanese Urological Association. The report of clinical statistical studies on registered bladder cancer patient in Japan 1993; p. 14.
8. Hodson NJ, Husband JE, MacDonald JS. The role of computed tomography in the staging of bladder cancer. Clin Radiol 1979; 30: 389-95.
9. Prout GR Jr. Bladder carcinoma and a TNM system of classification. J Urol 1977; 117: 583-8.
10. WHO Handbook for reporting results of cancer treatment. Geneva: WHO Offset Publication, 1979; 48: 27.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-63.
12. Chen HS, Gross JF. Intra-arterial infusion of anticancer drugs. Cancer Treat Rep 1980; 64: 31-5.
13. Collins JM. Pharmacokinetic rationale for intraarterial therapy. In: Howell SB, ed. Intra-arterial and intracavitary cancer chemotherapy. Boston. Martinus Nijhoff, 1984; 1-10.
14. Wallace S, Chuang VP, Samuels M, Johnson D. Transcatheter intraarterial infusion of chemotherapy in advanced bladder cancer. Cancer 1982; 49: 640-5.
15. Stewart DJ, Futter N, Maroun JA, Murphy P, McKay D, Rasuli P. Intra-arterial cisplatin treatment of unresectable or medically inoperable invasive carcinoma of the Bladder. J Urol 1984; 131: 258-26.
16. Galetti TP, Pontes JE, Motie J, Medendorp SV, Bukowski R. Neoadjuvant Intra-arterial chemotherapy in the treatment of advanced Transitional cell carcinoma of the Bladder: Results and follow-up. J Urol 1989; 142: 1211-5.
17. Jacobs SC, Menashe DS, Mewissen MW, Lipchik EO. Intraarterial cisplatin infusion in the management of transitional cell carcinoma of the bladder. Cancer 1989; 64: 388-391.
18. Nicolaos EM, John TH. Platinum nephrotoxicity.
19. Rozan R, Albuisson E, Donnarieix D, et al. Interstitial iridium-192 for bladder cancer (a multicentric survey: 205 patients). Int J Radiation Oncology Biol Phys 1992; 24: 469-77.
20. Slack NH, Prout GR Jr. The heterogeneity of invasive bladder carcinoma and different response to treatment. J Urol 1980; 123: 644-52.
21. Shipley WU, Coombs LJ, Einstein AB Jr, Soloway MS, Wajsman Z, Prout GR Jr and National bladder cancer collaborative group A. Cisplatin and full dose irradiation for patients with invasive bladder carcinoma. A preliminary report of tolerance and local response. J Urol 1984; 132: 899-903.
22. Marshall VF. Current clinical problems regarding bladder tumors. Cancer 1956; 9: 543.
23. Goldie J, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-33.
24. Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M - VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 1988; 139: 470-4.
25. Sternberg CN, Yagoda A, Scher HI, et al. M - VAC (methotrexate, vinblastin, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461-9.
26. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Pilat S. Cisplatin, cylophosphamide and doxorubicin chemotherapy for unresectable urethelial tumors. The M.D. Anderson Hospital experience. J Urol 1989; 141: 33-7.
27. Tannock I, Gospodarowicz M, Connolly J, Jewett M. M - VAC (methotrexate, vinblastin, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 1989; 142: 289-92
28. Stewart DJ, Benjamin RS, Zimmerman S, et al. Clinical pharmacology of intraarterial cisdiamine dichloroplatinum (II). Cancer Res 1983; 43: 917